Literature DB >> 629276

The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study.

A E Appel, L B Sablay, R A Golden, P Barland, A I Grayzel, N Bank.   

Abstract

A prospective study was carried out in 25 patients with systemic lupus erythematosis (SLE) on the effect of normalizing serum complement (CH50) and anti-DNA antibodies on the course of lupus nephritis. In 16 of the 25 patients, CH50 was maintained within the normal range for two years. Urinary protein excretion increased or remained low in all 16. Repeat renal biopsies were performed in 10 of these 16, and disclosed either stabilization of glomerular disease or diminution. In the nine patients in whom CH50 could not be normalized with tolerated doses of drugs, urinary protein excretion increased or remained increased. Repeat renal biopsies in six of these nine patients were carried out and showed worsening of glomerular disease in five. No clear-cut correlation was found between urinary protein excretion or renal disease and the serum levels of anti-DNA antibody. We conclude from these observations that continuous normalization of CH50 by drug therapy in patients with SLE is associated with stabilization or diminution of lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 629276     DOI: 10.1016/0002-9343(78)90056-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Comparison of a fluorometric method with radial immunodiffusion assays for determination of complement components C3 and C4.

Authors:  M Koelle; W R Bartholomew
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

3.  Complement depletion accelerates the clearance of immune complexes from the circulation of primates.

Authors:  F J Waxman; L A Hebert; J B Cornacoff; M E VanAman; W L Smead; E H Kraut; D J Birmingham; J M Taguiam
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

4.  Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis.

Authors:  E H Garin; J W Sleasman; G A Richard; A A Iravani; R S Fennell
Journal:  Eur J Pediatr       Date:  1986-10       Impact factor: 3.183

5.  Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus.

Authors:  J B Lefkowith; M Kiehl; J Rubenstein; R DiValerio; K Bernstein; L Kahl; R L Rubin; M Gourley
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

6.  Prognostic value of anti-dsDNA in SLE.

Authors:  A J Swaak; J Groenwold; L A Aarden; L W Statius van Eps; E W Feltkamp
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

7.  Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology.

Authors:  M Okamura; Y Kanayama; K Amastu; N Negoro; S Kohda; T Takeda; T Inoue
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

8.  Spontaneous plaque forming cells in the peripheral blood of patients with systemic lupus erythematosus.

Authors:  A G Wangel; A Milton; J B Egan
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

9.  International validation of a urinary biomarker panel for identification of active lupus nephritis in children.

Authors:  Eve Mary Dorothy Smith; Andrea Lyn Jorgensen; Angela Midgley; Louise Oni; Beatrice Goilav; Chaim Putterman; Dawn Wahezi; Tamar Rubinstein; Diana Ekdawy; Rachel Corkhill; Caroline Ann Jones; Stephen David Marks; Paul Newland; Clarissa Pilkington; Kjell Tullus; Michael William Beresford
Journal:  Pediatr Nephrol       Date:  2016-09-03       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.